¿Aún no está registrado?

Cree su cuenta. Regístrese en Elsevier y obtendrá: información relevante, máxima actualización y promociones exclusivas.

Registrarme ahora
Ayuda - - Regístrese - Teléfono 902 888 740
Buscar en

FI 2016

© Thomson Reuters, Journal Citation Reports, 2016

Indexada en:

Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, SCOPUS, Medes, Science Citation Index Expanded.


  • Factor de Impacto: 1,042(2016)
  • 5-años Factor de Impacto: 0,989
  • SCImago Journal Rank (SJR):0,24
  • Source Normalized Impact per Paper (SNIP):0,583

© Thomson Reuters, Journal Citation Reports, 2016

Aten Primaria 2006;38:387-91 - DOI: 10.1016/S0212-6567(06)70530-3
Hiperplasia benigna de próstata. Necesidad de valorar la calidad de vida en el proceso terapéutico
Benign Prostate Hyperplasia. Need to Evaluate Quality of Life in the Therapeutic Process
Francesc Bobé Armanta, M Eugenia Buil Arasanzb, Ana Isabel Allué Builc, Amàlia Morro Graua, Mónica Maxenchs Estebana, Montserrat Gens Barberàd
a EAP T??rraco. Institut Catal?? de la Salut. Tarragona. Espa??a.
b ABS La Granja-Torreforta. Institut Catal?? de la Salut. Tarragona. Espa??a.
c ABS Martorell. Institut Catal?? de la Salut. Barcelona. Espa??a.
d ABS Salou. Institut Catal?? de la Salut. Tarragona. Espa??a.
Objective. To relate the symptoms of benign prostate hyperplasia (BPH) to their repercussions on quality of life. Design. Multi-centred, observational, prospective study. Setting. Primary care. Participants. Men with BPH in 2000-2003. Inclusion criteria were: agreeing to take part, being aged 50-79, and having moderate symptoms evaluated by means of the IPSS questionnaire. Exclusion criteria. Previous treatment for BPH and having a chronic or disabling illness that might affect perception of quality of life. The presence of irritative and obstructive symptoms was appraised. Main measurements. The IPSS questionnaire appraising predominant symptoms and, through the last question, quality of life was self-administered. Descriptive statistics were worked out and differences in proportions of the different groups were analysed by the χ2 test, with differences taken as significant at P<.05. Results. We got 536 replies, with average age 66.2. Nycturia was the most common symptom, suffered by 88.1% of patients. A total of 256 patients (47.8%) had irritation as main clinical symptom, and 280 (52.2%), obstruction. On analysing repercussions on quality of life, it was found that obstructive symptoms were worse tolerated: 65.7% versus 9.4% of the group with irritation. Conclusions. In treating BPH, we must bear in mind preferences of patients. They tolerate obstructive symptoms worse, and these are a criterion for referral to specialists and even surgery.
Palabras clave
Calidad de vida, Hiperplasia benigna de próstata, IPSS, Tratamiento, Atención primaria
Quality of life, Benign prostate hyperplasia, IPSS, Therapy, Primary care